Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Share-based Compensation (2017 - 2025)

Sutro Biopharma's Share-based Compensation history spans 9 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 76.29% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $18.3 million, down 26.91%, while the annual FY2024 figure was $24.7 million, 0.89% down from the prior year.
  • Share-based Compensation for Q3 2025 was $1.6 million at Sutro Biopharma, down from $5.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.0 million in Q1 2022 and bottomed at $1.6 million in Q3 2025.
  • The 5-year median for Share-based Compensation is $6.1 million (2024), against an average of $5.9 million.
  • The largest annual shift saw Share-based Compensation soared 123.1% in 2021 before it crashed 76.29% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $6.9 million in 2021, then decreased by 15.03% to $5.9 million in 2022, then rose by 6.34% to $6.2 million in 2023, then decreased by 4.95% to $5.9 million in 2024, then plummeted by 73.76% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Share-based Compensation are $1.6 million (Q3 2025), $5.3 million (Q2 2025), and $5.5 million (Q1 2025).